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number of chemotherapeutic agents. Several oligomeric states of ABCG2 from homodimers to dodecamers
have been reported depending on the overexpression systems and/or the protocols used for puriﬁcation.
Here, we compared the oligomeric state of His6-ABCG2 expressed in Sf9 insect cells and in human Flp-In-
293/ABCG2 cells after solubilization in mild detergents. His6-ABCG2 was puriﬁed through a new approach
involving its speciﬁc recognition onto a functionalized lipid layer containing a Ni-NTA lipid. This approach
allowed the puriﬁcation of His-ABCG2 in presence of all solubilized membrane components that might be
involved in the stabilisation of native oligomers and without requiring any additional washing or
concentration passages. ABCG2 puriﬁed onto the NiNTA lipid surfaces were directly analyzed by electron
microscopy and by biochemical assays. Altogether, our data are consistent with a tetrameric organization of
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The ability of cells to acquire a multidrug resistance (MDR) phe-
notype is often related to overexpression within their plasma
membranes of ATP-binding cassette (ABC)-transporters able to efﬂux
many chemotherapeutic drugs at the expense of ATP hydrolysis. More
recently than P-glycoprotein/ABCB1 and MRP1 (multidrug resistance
protein)/ABCC1, breast cancer resistance protein/ABCG2 has also been
shown to be associated to an MDR phenotype. The common overall
topology of ABC transporters is constituted by two hydrophobic do-mains that contain drug-binding sites, and two cytoplasmic nucleotide-
binding domains (NBDs) that contain the hydrolytic sites. Unlike ABCB1
and other “full” transporters, the predicted topology of ABCG2, ~ 72 kDa,
comprises one hydrophobic domain of six transmembrane helices and
one cytosolic NBD. Moreover, ABCG2 displays a reverse arrangement
with the N-terminal NBD region preceding the transmembrane domain
(TM), in comparison to many other ABC transporters. Since two NBDs
are required for ATP hydrolysis and substrate transport [1], it is believed
that the minimal functional unit of ABCG2 is a dimer. This assumption
has also been supported by experiments reporting the co-immunopre-
cipitation of wild-type and mutated proteins [2], and by the functional
expression of dimeric chimera [3]. Moreover the transmembrane
dimerization motif GXXXG [4], G553 residue within TM5 [5] or
intermolecular disulﬁde bridges involving Cys603 inside the loop
connecting TM5 and TM6 [6,7], have been proposed as molecular
basis for ABCG2 dimerization.
However, higher oligomeric states of ABCG2 including tetrameric,
octameric and dodecameric forms have also been reported [8–10]
raising the question whether they were indeed present in the native
membrane with functional relevance. The tendency of ABC membrane
transporters to formmultimers has alsobeen reported forMRP1 [11,12],
CFTR [13] or the yeast Pdr5p full-transporter [14]. Furthermore,
transition from dimers to higher oligomeric states during the ATPase
cycle has also been reported for ABCA1 [15].
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ABCG2 is complicated by the fact that proteins have been expressed in
different overexpression systems and analyzed by different biochem-
ical approaches, i.e. just after extraction from the membrane or after
puriﬁcation in detergent. Tetramers and dodecamers were reported
for transporters expressed in human cell lines, where proteins were
extracted from the membrane but not puriﬁed in detergent, and
analyzed by perﬂuoro-octanoic acid gels and non denaturating gel
electrophoresis [8,9]. Octamers of ABCG2 have been reported after
high expression in High-Five insect cells, puriﬁcation in Fos-choline
16 and 3D reconstruction by electron microscopy [10] while
progesterone-induced tetramers were puriﬁed after expression in
Lactococcus lactis [16].
Here, we compare the oligomeric state of ABCG2 expressed in both
Sf9 insect cells and in human Flp In-293 cell lines, two expression
systems allowing a functional expression of ABCG2. Moreover, we
puriﬁed ABCG2 using a new approach of puriﬁcation, based on the
speciﬁc binding of His6-ABCG2 to a functionalized lipid layer. The
puriﬁcation was performed in presence of all membrane components
including lipids and bypassing any further puriﬁcation or concentra-
tion steps. The biochemical and electron microscopy analyses of
ABCG2 are consistent with a tetrameric organization of ABCG2 after
expression in both Sf9 insect cells and Flp-In-293/ABCG2 cell lines.
2. Material and methods
2.1. Materials
Dioleyl-phospatidyl choline (DOPC) and Ni-nitrilotriacetic-1,2-
dioleoyl-sn-glycero-3-{[N- (5-Amino-1-carboxypentyl) iminodiacetic
Acid]Succinyl} (Ni++-NTA-DOGS) were of the highest purity avail-
able, and purchased from Avanti Polar Lipids (AL, USA). Detergents,
dodecyl-β-D-maltoside, DDM, dodecyl-β-D-thiomaltoside, DOTM,
Fos-choline 16, n-Hexadecylphosphocholine and 3-[(3-cholamido-
propyl) dimethylammonio]-1-propanesulfonate CHAPS were pur-
chased from Anatrace (OH, USA). The protease inhibitor cocktail for
eukaryotic proteins was from Sigma Aldrich. Monoclonal antibodies
BXP-21, 5D3 and anti-His, were purchased from Alexis (CA, USA),
Pierce (IL, USA) and BiolLegend (CA, USA), respectively.
2.2. Expression of ABCG2 in Sf9 insect cells
Human ABCG2 was expressed in Sf9 insect cells according to [17].
Brieﬂy, the expression plasmid pFastBac Dual–NinaA + ABCG2 was
derived from the expression plasmid pTriEx-BCRP and the addition of
ABCG2 at its N terminus [18]. The resulting sequence was
mahhhhhhssgketaaakferqhmdspppsglvprgssS4 ABCG2-S655 which in-
cluded a hexa-histidine afﬁnity tag. Cells were infected with
baculovirus at a multiplicity of 0.1 at 27 ° C and harvested 72 h
post-infection. The pellets were washed twice with ice cold
Dulbecco's phosphate buffer saline without CaCl2 and MgCl2, then
suspended in 20 mM Tris-HC1, pH 8.0, 10 mM NaCl, 1 mM MgC12,
200 μMDTT, and incubated on ice for 30 min. Cells were suspended in
lysis buffer (10 mM HEPES/NaOH, 10 mM NaCl, pH 8) for 1 h at 4 °C,
then lysed by 20 passages through a 25Gx5/8” syringe needle. Cellular
debris were pelleted by centrifugation at 500×g for 15 min and
discarded. The supernatant was centrifuged at 15 000×g for 1 h. Then,
the supernatant was centrifuged at 100 000×g for 1 h to obtain a
pellet of enriched plasma membranes. Finally, membranes were snap
frozen in liquid nitrogen and stored at -80 °C. All steps were
performed in presence of 10 μl/ml buffer of the protease inhibitor
cocktail. ATPase activity of ABCG2 in Sf9 membranes was measured as
described below to 12 nmol.mg-1.min-1 and was consistent with the
ATPase activities reported by [4]. This corresponded to a turnover
number of 0.89 min-1 per monomer, i.e. 3.4 min-1 per tetramer.2.3. Expression of His6- ABCG2 in Flp-In 293 cells
Flp-In-293 cells (Invitrogen) were transfected with the
ABCG2pcDNA5/FRT vector. The ABCG2pcDNA5/FRT vector was
obtained by a subcloning pFastBac Dual–NinaA + ABCG2 as
previously used for Sf9 insect cells. The resulting cells are described
hereinafter as Flp-In-293/ABCG2 cells. Flp-In-293/ABCG2 cells were
maintained in DMEM supplemented by fetal bovine serum (10%) and
penicillin/streptomycin (1%) and hygromycin (100 μg/ml) at 37 °C
under 5% CO2. Cells were seeded at 10 millions per hyperﬂask
(Corning) and maintained at 37 °C under 5% CO2. After 4 days cells
were harvested with 100 ml of PBS/EDTA and pelleted by centrifu-
gation (5 min, 1000×g, 4 °C). The cells were resupended in 10 ml of
lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl 1, 1 mM MgCl2, 1 mM
DTT, protease inhibitor) and incubated 1 h in ice. The cells were
disrupted on ice by 10 repeated strokes of a Dounce homogenizer
with pestle B. Membranes were prepared as previously described for
Sf9 membranes. The ATPase activity of ABCG2 in Flp-In-293/ABCG2
membranes was measured as described below to 10 nmol/mg/min.
2.4. Solubilization of membranes
Plasma membranes were resuspended at 2 mg protein/ml in
20 mM MOPS, ph 7.4, 200 mM NaCl, 2.5 mM MgCl2, 10% glycerol,
1 mM PMSF, antiprotease cocktail (10 μl/ml buffer). Membraneswere
solubilized for 1 h at 4 °C in different detergents at deﬁned detergent/
total protein ratio before centrifugation at 60 000 rpm for 30 min.
Supernatants and pellets were analyzed by both SDS-PAGE and
immunoblot.
For SDS PAGE, protein samples, at 0.1-1 μg per lane, were loaded on
a 8% sodium dodecylsulfate (SDS)-polyacrylamide gel immediately
after the addition of loading buffer at 4 °C containing 2% SDS, 1% β-
mercaptoethanol, 50 mM, Tris-HCl, pH 6.8, and submitted to
electrophoresis at 200 V for 45 min at room temperature. The gels
were revealed by silver staining. The high molecular band of ABCG2
above 250 kDa molecular marker was only seen on the SDS-PAGE gel
when samples were not boiled.
For immunoblot, gels were submitted to 15 mA over night transfer
at 4 °C onto PVDF membranes, and ABCG2 bands were revealed after
incubation with a mouse anti-ABCG2 monoclonal antibody BXP-21 at
1:700 dilution, for 1 h at room temperature, followed by an anti-
mouse goat IgG (Fab speciﬁc)-alkaline phosphatase (AP) conjugate
secondary antibody used at 1:10000 dilution. Alternatively, the
protein was revealed using the anti-His HisProbe-HRP without
signiﬁcant differences.
Blue native gels were performed combining the addition of Serva
Blue G in the cathode buffer with a discontinuous buffer system and
gradient gel as proposed in [19]. Brieﬂy, 12 μl of solubilized
membranes were mixed with one volume of 4 X loading buffer,
250 mM Tris pH 6.8, 40% glycerol, 0.002% bromophenol blue, and
loaded onto a 4-14% gradient of a Laemmli polyacrylamide gel
without SDS. Electrophoresis was performed at 4 ° C at a constant
voltage of 80 V with Blue running buffer in the cathode chamber,
25 mM Tris, 198 mM glycine, pH 8, 0.02% Coomassie Serva Blue G,
replaced by running buffer without the blue stain after front gel
migration to the middle of the gel. Immunodetection of ABCG2 was
performed as described above. The conditions of running were
carefully optimized with high molecular weight calibration kit for
native electrophoresis (GE Healthcare, UK) and with membrane
proteins solubilized in DOTM including BmrA, a bacterial homo-
dimeric ABC half-transporter of 130 kDa [20] and either monomeric
(280 kDa) or and dimeric (560 kDa) LH1-RC core complex form Rba.
sphaeroides [21] (see calibration curve SD1). In experiments
performed to evaluate the formation of disulﬁde bridges during the
solubilisation step, membranes were solubilized for 1 h by DOTM or
DDM in a buffer supplemented with 10 mM N-ethylmaleimide.
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buffer, 250 mM Tris, pH 6.8, 40% glycerol, 5 mM NEM, 0.002%
bromophenol blue.
2.5. ATPase activity
The ATPase activity was measured with a colorimetric ascorbic
acid/ammonium molybdate assay of inorganic phosphate release
according to [18]. Membranes at 10 mg/ml were solubilized in DOTM
at a ratio detergent/protein of 5 w/w. After centrifugation at 100
000×g, the supernatant was supplemented with azolectin solubilized
in DOTM at 5 mg/ml ﬁnal lipid concentration. An aliquot of 20 μl, was
mixed with 40 μl of buffer containing 5 mM NaN3, 7 mM MgCl2,
5.5 mM ATP, 2 mM ouabain, 0.1 mM EGTA and 20 mM Tris/KCl.
Samples were incubated for 30 min at 37 °C and the reaction was
stopped by the addition of 30 μl 10% SDS before measurement of the
absorbance at 620 nm. The ATPase activity was calculated as the
difference of rates in presence and absence of 0.5 mM orthovanadate.
Sf9 His6-ABCG2 and Flp-In-293 His6-ABCG2 solubilized in DOTM
displayed a signiﬁcant ATPase activity of 6 nmol/mg/min and
5 nmol/mgr/min, respectively.
2.6. Binding of His6-ABCG2 to the Ni
++-NTA-DOGS lipid layer
A functionalized lipid layer containing Ni++-NTA-DOGS lipid was
used to speciﬁcally bind, concentrate and purify His6-ABCG2. This
lipid ligand that has been designed for the immobilization or the 2D
crystallization of his-tagged soluble proteins [22–25], is used here in
the case of membrane proteins solubilized in detergent. Brieﬂy, 0.5 μl
of Ni++-NTA-DOGS/DMPC (1/1 mol/mol) in CHCl3 at 0.1 mM was
spread at the air/water interface of a 50 μl Teﬂon well provided with a
side hole to allow further injections below the lipid monolayer of
solubilized proteins in detergent [26]. Due to the geometry of thewell,
i.e. the concavity of the surface, a slight excess of lipid of ~30%
compared to a monolayer of lipids at 45 A2/molecule, was spread to
ensure the formation of a compressed layer. This also often leads to
the formation of lipid aggregates at the surface as observed by
electron microscopy (Fig. 2B).
Moreover, as observed by us and others [26–29], it was important
to spread the lipid layer before the protein injection to stabilize of the
lipid layer in presence of detergent. Indeed, after injection of proteins,
molecules of detergent reach the surface and compress the lipid
monolayer forming condensed lipid domains surrounded by deter-
gent domains and resistant to the solubilization. On the opposite,
when lipid are spread onto a surface of detergent containing buffer,
micelles of detergent are already present and solubilize the lipid layer
[30].
For the puriﬁcation of His6-ABCG2 at the lipid surface, 5 μl of
solubilized membrane at 2 mg/ml in 1% DOTM were injected below
the lipid layer through the side hole of the well and incubated under
gentle stirring at 4 °C. Since all membrane proteins were present in
the well during the binding step, 5 mM imidazole was added to
decrease unspeciﬁc interactions. The buffer in the well, 50 mMMOPS,
pH 7.8, 150 mM KCl, 2.5 mM MgCl2, was also supplemented with the
10 μl/ml antiprotease cocktail to avoid degradation of proteins.
Surfaces were picked up after 24-h incubation at 4 °C. It should be
noted that detergent concentration after injection of the solubilized
membranes in the well remained far above the cmc, i.e. 0.1% DOTM,
corresponding to ~38 cmc value. Thus, all membrane proteins were
solubilized inmicelles of detergent during the binding step to the lipid
surface. In the case of the puriﬁcation of His6-ABCG2 solubilized in
DDM, Fos-choline 16 and CHAPS, 5 ul of solubilized membrane in 1%
DDM, 2%, Fos-choline 16 or 18 mM CHAPS were injected below the
lipid layer. The detergent concentrations in the wells were 0.1% DDM,
0.2% Fos-choline 16 and 8 mM CHAPS, respectively, corresponding to
13-fold, ~ 388-fold and 1-fold the cmc, respectively (Fig. SD3).In all experiments, proteins were present at the surface only when
Ni++-NTA-DOGS lipid was present in the composition of the
monolayer. No proteins were found at imidazole concentrations
above 20 mMor EDTA above 5 mM. Proteinswere found at the surface
of Ni++-NTA-DOGS lipid above 5% mol/mol and with DOPC or DMPC
as diluent lipid. However, no signiﬁcant differences were observed
with increasing amount of lipids spread at the surface from 0.1 mg/ml
solution to 0.5 mg/ml.
We also tried the puriﬁcation procedure using “afﬁnity” grids
developed by Kelly et al. [31] that consists of binding His-tagged
proteins onto a lipid layer previously deposited onto a carbon grid.
However, we did not ﬁnd recognisable proteins, likely due to a too
long time required for the binding of His6-ABCG2, i.e. several hours
that led to solubilization of the Ni++-NTA-DOGS lipids coated onto
the carbon grids.
2.7. Protein elution from EM grids for SDS-PAGE and EM analysis
Proteins were recovered from the Ni++-NTA-DOGS lipid layer as
described [32]. Brieﬂy, a surface with bound proteins was picked up
with a carbon-coated gold EM grid, carefully blotted with Whatman 4
ﬁlter paper and incubated with a 10 μl drop of the same buffer present
in the well including detergent, supplemented with 300 mM
imidazole. After 2-min incubation, the same drop was used for the
elution of proteins transferred onto a second grid until twenty-four
grids were used. The ﬁnal drop was analyzed by SDS-PAGE or used for
EM analysis.
2.8. Mass spectra
The putative band of ACBG2 (Fig. 2D, lane 2) was cut out and
subjected to an overnight in-gel trypsin treatment. Peptides were
analyzed by MALDI-MS, and sequenced by ES Q-Tof MS/MS analysis.
Protein identiﬁcation was achieved by mass ﬁngerprint of peptides
and comparison with the NCBI protein database using the Mascot
algorithm (Supplemental data SD2).
2.9. Immunolabeling of Sf9 His6-ABCG2
To ensure an unambiguous assignment of Sf9 His6-ABCG2
observed by EM, proteins bound to the lipid layer and transferred
onto carbon-coated grids were immunolabeled with 5D3, a speciﬁc
conformational anti-ABCG2 antibody, before labelling with Protein A
gold. Brieﬂy, grids with bound proteins were incubated for 10 min in
one drop of PBS-1% paraformaldehyde, then for 4 min in four drops of
PBS-100 mM glycine to quench the free aldehyde groups; ﬁnally, non-
speciﬁc sites were saturated by incubation for 10 min with 1% BSA
before binding of the 5D3 antibody at 1/50 dilution for 30 min. After
extensive rinsing with several PBS drops containing 0.2% BSA, a
second cross-linking, the anti-mouse rabbit, antibody at 1/200
dilution was added for 30 min before incubation with Protein A-
5 nm gold in PBS and 0.2% BSA for 20 min. After rinsing with PBS, the
labelling was stabilized with 1% glutaraldehyde before extensive
rinsing with water, and negatively staining with 1% uranyl acetate. A
higher amount of bound 5D3 antibody was foundwhen proteins were
ﬁrst incubated in presence of 1% paraformaldehyde before labelling, in
agreement with the increase of labelling observed in ABCG2-
expressing PLB985 cell line [33]. In the absence of antibodies, less
than 5% of gold particles by comparison to the labelling with 5D3 anti-
ABCG2were found at the surface. All buffers were supplemented with
0.01% DOTM.
2.10. Electron microscopy analysis
Sf9 His6-ABCG2 bound to the surface of Ni++ -NTA lipids were
transferred onto a carbon-coated grid and negatively stained with 1%
Fig. 1. Solubilization and assignment by biochemical assay of the oligomeric state of
His6-ABCG2 expressed in Sf9 insect cells. (A) Solubilization of membranes and western
blot of His6-ABCG2. Membranes resuspended at 2 mg protein/ml were solubilized in 1%
DOTM, 1% DDM, 1% Fos-choline 16, and 18 mM CHAPS, 1% undecylmatoside (11DM),
1% decylmatoside (10DM), 1% Triton X100. For each detergent, 10 μl of supernatant
(left) and pellet (right) were analyzed by 8% SDS-PAGE and His6-ABCG2 was revealed
using the BXP-21 speciﬁc antibody and running at ~70 kDa. (B) 4-14% blue native gel of
solubilized His6-ABCG2 and, for comparison, the homodimeric bacterial ABC trans-
porter, His6-BmrA (MW 130 kDa) puriﬁed in DOTM (lane 1). Immunoblot of
membranes solubilized in DOTM in either absence or presence of 5 mM NEM (lanes 2
and 3 respectively) and solubilization in DDM (lane 4). Note that lanes have been
immunlolabeled separately with anti-Hist antibody for BmrA and with BXP21 for
ABCG2.
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1024×1024 px ssCCD Gatan camera on a CM120 Philips microscope
operating at 120 kV for images depicted in Fig. 2, and with a 2040 x
2048 ssCCD GATAN camera on a JEOL 2200 FS operating at 200 kV for
single particles analysis. For the latter, pixel size was calibrated with
2D crystals of purple membrane leading to a pixel size of 2.47 Å/pixel
at 40000 X. Images were taken at 0.75-1.2 μm defocus.
2D images analysis was performed using Xmipp package [34]. The
intermediate results of the procedure are shown in the Supplemental
Data SD5. Brieﬂy, a total of 1694 images of bound Sf9 His6-ABCG2
corresponding to the extracellular views were windowed 100×100
pixels. Particles were masked with an external radius of 89 Å to
discard the contribution of the nearest particles. Final self-organizing
mapping [35] leads to three groups of images. The ﬁrst one
corresponds to distorted or uneven stained particles and was further
discarded, whereas the two others, representing 81% of the popula-
tion, were pooled. A free alignment reference was applied and the
ﬁnal average image was calculated without symmetry imposition and
ﬁltered at the 22 Å resolution estimated according to the FSC 0.5
criteria.
The NBDs views were obtained after elution of the bound proteins
and coating onto a new grid. A set of 42 and 55 images of ABCG2
expressed in Sf9 and in Flp-In-293/ABCG2 cells, respectively, were
easily recognisable and assigned to NBD views according to previous
works [14,36], were centred and free reference aligned. The spectra
analysis revealed a four-fold symmetry. After averaging, this symme-
try was applied and the average image was ﬁltered at the FSC 0.5
criteria estimated resolution of 31 Å. Extracellular views present on
the same grid of eluted proteins were also analyzed. Particles were
similar in size, 12 nm in diameter, and with a circular shape than the
extracellular views of particles bound to the lipid layer (data not
shown).
3. Results and Discussion
As already been shown, ABCG2 can be overexpressed in either Sf9
or High-Five insect cells as a fully functional protein [37,38]. However
overexpression in High-Five cells led to two ABCG2 species, one of
which was immature and could not be solubilized in mild detergents
[18,39] but required SDS or Fos-choline 16 to be extracted [10]. We
therefore used Sf9 cells where the protein synthesis rate was lower
but produced ABCG2 as single functional specie, as shown in the
western blot of solubilized plasma membranes (Fig. 1.A).
Flp-In-293/ABCG2 cells were used for the overexpression of
ABCG2 in human cell lines. Flp-In-293/ABCG2 cells were derived
from the HEK 293 cell lines and provided the complete machineries
for the correct glycolysation, plasma membrane targeting and folding
for the transporter [40].
3.1. Solubilization of Sf9 His6-ABCG2
Solubilization trials were performed with several low cmc
detergents. The protein with the band running at ~72 kDa, the
expected molecular weight of His-ABCG2 expressed in Sf9, was
revealed by western blot using BXP-21, a speciﬁc ABCG2 monoclonal
antibody. The detergents used were DDM, DOTM, undecylthiomalto-
side, decylthiomaltoside, Triton X100, and ﬁnally Fos-Choline 16 and
CHAPS that were previously used for the solubilization of ABCG2
expressed in High-Five insect cells [10,18].
At a detergent/protein ratio of 5 (w/w) almost all His6-ABCG2was
solubilized with any tested detergents except for CHAPS (Fig. 1A).
His6-ABCG2 was also completely solubilized at detergent/protein
ratios of 2.5 w/w with DDM, Fos-choline 16 and Triton X 100 but to a
lower extent with DOTM. Increasing the CHAPS concentration up to
2% increased the solubilization yield but still remaining less efﬁcient
than other detergents at 1% (data not shown). This is signiﬁcantlydifferent from the data reported with ABCG2 expressed in High-Five
insect cells highlighting the different composition of membranes and/
or the membrane preparations.
We performed the next experiments with DOTM, a mild detergent
similar to DDM that was shown to stabilize large membrane protein
complexes [41,42] and with DDM without signiﬁcant differences.
The oligomeric state of ABCG2 solubilized in DOTM was next
characterized by blue native gel. The conditions of running were
carefully optimized with calibration markers and with membrane
proteins solubilized in DOTM including BmrA, a bacterial homo-
dimeric ABC half-transporter of 130 kDa (Fig. 1B, lane 1, and
calibration curve in Supplemental data SD1). A single band of His6-
ABCG2 solubilized in DOTM and in DDM (Fig. 1B, lanes 2 and 4
respectively) was found at ~290 kDa between the molecular markers
at 140 kDa and 440 kDa. These bands running signiﬁcantly above the
homodimeric BmrA were assigned to tetramers of ABCG2. Moreover,
no additional bands at higher molecular weights that would be
associated with higher oligomeric states, such as octamers or
dodecamers, were found.
Solubilizations in DOTM were also performed in presence of the
alkylating agent NEM that prevents the formation of disulﬁde
bridges. The tetrameric band was still present and no additional
bands at lower molecular weights were found revealing that
tetramers of ABCG2 were the only oligomers extracted from the
membrane (Fig. 1 C, lane 3).3.2. Puriﬁcation of Sf9 His6-ABCG2 onto functionalized lipid layer
The classical protocols of puriﬁcation of His6-ABCG2 usually
involved the binding of protein onto a Ni++-NTA agarose resin,
then a washing step to eliminate contaminants and after elution with
imidazole, a concentration step onto calibrated membranes. It cannot
be ruled out that, during the successive steps of puriﬁcation, the
oligomeric state might change as due to either loss of important
compounds, partners, or the variations in the detergent/protein ratio.
We thus developed a new protocol of puriﬁcation based on the
speciﬁc recognition of proteins onto a functionalized lipid layer.
This approach consists in spreading a lipid layer containing Ni++-
NTA–DOGS, a lipid bearing a Ni++-NTA group, at the air/buffer
interface of a Teﬂon well. This ligand is similar to the Ni++-NTA
group used in classical afﬁnity chromatography, in order to bind
and purify His-tagged membrane proteins. This approach combines
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His-tagged puriﬁed membrane proteins [26,27] and that related to
the puriﬁcation of aquaporin AQP0 after few minutes incubation
onto a functionalized lipid layer deposited onto a carbon grid [31].
The crucial improvement compared to the latter consisted in a
much longer incubation time allowing the binding of membrane
proteins either with a low-afﬁnity tag or expressed in very low
amount.
Here, membranes were solubilized in 1% DOTM and after the
centrifugation step necessary to remove non-solubilized proteins, a
few μl of supernatant were injected below the lipid layer through a
side hole (Fig. 2A). As observed in the case of the 2D crystallization of
membrane proteins, the lipid layer was stable for several days in
presence of detergent when the lipid layer was formed before
injection of the protein, whereas it was rapidly solubilized if lipids
were spread directly onto a buffer containing the detergent
[27,28,30]. After overnight incubation at 4 °C in presence of
antiproteases, the surface was picked up with a carbon-coated grid
and analyzed by either EM or biochemical methods.
EM analysis of the transferred surface revealed homogeneous
population of circular-shaped particles of ~12 nm in size (Fig. 2B)
coexisting with recognisable lipid aggregates (large white areas). The
presence of the 12 nm particles was found speciﬁc to the presence of
both His6-ABCG2 and Ni++-NTA-DOGS lipid. No protein was found at
the surface without Ni++-NTA-DOGS lipid or after incubation with a
buffer supplemented with imidazole at a concentration above 20 mM.
Proteins bound to the surface were immunolabeled with 5D3, a
conformational anti-ABCG2 antibody, followed by the binding of
protein A gold. Proteins appeared more aggregated in patches than
before labelling, likely due to the successive washing steps including
the ﬁxation step in paraformaldehyde. However, several particles
were successfully gold labelled demonstrating that the 12 nm
particles were indeed ABCG2 (Fig. 2C).
The protein composition at the surface was further analyzed by
SDS-Page after elution of bound proteins with a buffer supplemented
with 300 mM imidazole.
The SDS-PAGE analysis of proteins bound to lipid surface showed a
drastic puriﬁcation of the membrane content (Fig. 2D). Indeed, onlyFig. 2. Single-step puriﬁcation of His6-ABCG2 expressed in Sf9 membrane by using a function
layer. Solubilized membranes in DOTM containing Sf9 His6-ABCG2 (1) was injected in a Te
the surface was picked up with a carbon-coated grid (3) and analyzed by electron microsco
(4). (B) Electron micrograph of Sf9 His6-ABCG2 bound to the lipid layer after incubation o
with the conformational 5D3 anti-ABCG2 and protein A gold; gold particles appeared as bla
Lane 1: solubilizedmembranes before incubation with the lipid layer. Lane 2: proteins bound
a main band above 250 kDa (***) likely corresponding to the monomeric and oligomeric ABthree bands were present: a well deﬁned band above 250 kDa (***), a
faint band at ~72 kDa (*) corresponding to themonomeric ABCG2 and
a band below ~60 kDa likely corresponding to unspeciﬁcally bound
contaminants. By contrast, ABCG2 expressed in High-Five cells and
puriﬁed with Ni++-NTA agarose resins contained more contaminants
and required further puriﬁcation by anionic exchange and size
exclusion chromatography to eliminate them [10]. Since the same
types of speciﬁc interactions were involved at the lipid layer surface
and on the agarose beads, i.e. Ni++-NTA-polyHis interactions, the
observed differences might be related to the known capacity of
eukaryotic membrane protein to unspeciﬁcally bind to agarose beads.
The band above 250 kDa was analyzed by mass spectra that
revealed peptide fragments ambiguously speciﬁc to ABCG2 (Supple-
mentary material SD2). A similar band of ABCG2 above 250 kDa has
also been reported by others in cross-linking experiments and
considered as either deﬁned oligomers or as aggregates [3,5,8,43].
Here, electron microscopy show that the high molecular band
correspond to well deﬁned particles of ABCG2 of 12 nm that could
not be assigned to aggregates.
We also examined the oligomeric state of Sf9 His6-ABCG2
solubilized in other detergents. Experiments of binding to the Ni++-
NTA lipid layer were performed with solubilized membranes and the
presence of His6-ABCG2 was evaluated by EM (Supplemental data,
SD3). A similar large amount of ABCG2 bound to the surface was
found when starting from membranes solubilized in either DOTM or
DDM. In the case of membranes solubilized in Fos-choline 16 and in
CHAPS, EM analysis has shown that the lipid layer was unstable.
However, fewer particles of ABCG2 but of similar circular shapedwere
found (data not shown). With all detergents, the size of 11-12 nm
diameter and the shape of the particles are similar to tetramers ABCG2
and are larger and smaller than dimers or octamers, respectively. It
this thus likely that the oligomeric state of Sf9 ABCG2 as puriﬁed at
the lipid surface was constant and not related to the detergent used
for membrane extraction.
Finally, we controlled if the lipid layer allowed the puriﬁcation
of other membrane proteins and if the binding and the concentration
of proteins at the surface did not induce artefactual oligomeric
states. E. coli membranes expressing His6-BmrA were solubilized inalized lipid layer. (A) Principle of the puriﬁcation at the surface of a functionalized lipid
ﬂon well below a lipid layer containing a Ni++-NTA-DOGS lipid (2). After incubation,
py or by 8% SDS-PAGE after elution with a drop of buffer containing 300 mM imidazole
f the total solubilized membranes. Bar=25 nm. (C) Same grid after immunolabelling
ck dots. (D) Silver stained SDS-PAGE of proteins bound to the Ni++-NTA DOGS surface.
at the lipid surface. Two bands were found above 60 kDa, a faint band at ~70 kDa (*) and
CG2, respectively.
2099M. Dezi et al. / Biochimica et Biophysica Acta 1798 (2010) 2094–2101DOTM and incubated with Ni++-NTA DOGS lipid layer. After elution
of bound proteins, SDS-PAGE analysis revealed a successful puriﬁ-
cation with only two bands, His6-BmrA and a single contaminant
(Supplemental data, SD4). Furthermore, electron microscopy of the
surfaces showed small particles consistent with dimeric BmrA
without larger particles. The dimeric form of BmrA was also found
in the native gel of solubilized membranes (SD4, Supplemental data,
SD4) and from the projection calculated from 2D crystals of puriﬁed
BmrA and reconstituted at the lipid layer [20,27].
3.3. Electron microscopy of Sf9 His6-ABCG2
3.3.1. Extracellular side
Sf9 His6-ABCG2 bound to the lipid layer were imaged by EM after
negative staining and analyzed using a single particle approach.
Almost all images showed the similar feature of circular particles of
~12 nm diameter with a large internal cavity of 6-7 nm (Fig. 3A). His6-
ABCG2was bound to the surface through its His6 extension present on
the N-terminal cytoplasmic side close to the NBD. In this orientation,
the extracellular side is facing the bulk in the Teﬂon well and after
transfer onto the carbon grids, this side was accessible to the negative
staining. It is thus likely that the images corresponded to the extra-
cellular views as also shown by the immunolabelling experiments
(Fig. 2). Although particles appeared similar in shape, we performed a
detailed analysis to identify homogenous populations. We classiﬁed
particles according to their symmetry using a self-organize mapping
approach. This led to 15 classes of proteins, all showing a similar
average imagewith differences due to slightly different tilts relative to
the surface (see also Supplemental data SD5). An average image of the
closest populations was calculated at 22 Å resolution (Fig. 3C). The
extracellular side appeared as an almost continuous circular shaped
protein of 11.5 nm diameter with extensions up to 13.5 nm and an
internal region of stain-penetrating region of 7.5 nm in diameter. Part
of the external extensions corresponded to the contribution of the
cytoplasmic NBDs (see below).
The continuous ring of densities was strikingly different from
known structures of other ABC exporters. The periplasmic side of
Sav1886, in an open outward conformation, showed two separated
bundles of helices that would appear as two separated densities in the
extracellular projection of negatively-stained ABCG2 at 22 Å resolu-Fig. 3. Electron microscopy analysis of negatively stained His6-ABCG2 puriﬁed from Sf9
membranes. (A) Gallery of extracellular views of His6-ABCG2 bound to the Ni++-NTA
lipid layer. (B) Gallery of NBDs views of His6-ABCG2 eluted from the lipid layer. The
dimensions of the images are 180 Å x 180 Å. (C) Average image of the extracellular side
of His6-ABCG2. (D) The 4-fold symmetrized average image of the NBD side of His6-
ABCG2. Scale bar=5 nm.tion [44]. A single broad density would be expected from the
periplasmic side of MsbA homodimer and of the monomer of Pgp in
open inward conformation [45,46]. However, it is worth mentioning
that ABCG2 contains an additional extracellular large loop ECL3, of
~55 amino-acids, between TMD5 and TMD6. This loop contains the
epitope of the 5D3 antibody that was bound to the extracellular side of
ABCG2 at the lipid layer (Fig. 2C). We propose that the continuous
densities along the extracellular view likely result from the ELC3
loops. In this context, the yeast full transporter Pdr5p, with the same
reverse topology as ABCG2, and with two large loops between TMD5
and TMD6 and between TMD11 and TMD12, also show rather large
extracellular continuous densities [14].3.3.2. Intracellular side
To get other views of ABCG2, proteins bound to the surface were
transferred onto a carbon-coated grid, eluted and deposited onto a
new carbon grid. Very few particles were found on the grid likely due
to the low concentration of eluted protein in the drop. Most views
were extracellular view indicating a preferential coating of ABCG2
onto the carbon grid. However, particles with a recognizable NBDs
view were also present. They showed a square shaped protein of
15 nm width with a central stain penetrating region of 2.5 nm
(Fig. 3B). Symmetry analysis revealed a 4-fold symmetry particle. The
4-fold symmetrised average at 31 Å resolution is depicted in Fig. 3D.
The resolution was rather low but however sufﬁcient to delineate the
different subdomains. The four densities of 6 nm diameter were
consistent with the 5-6 nm diameter size of the single NBD observed
by electron microscopy as reported for the yeast ABC transporter
Pdr5p [14] and for BmrA [20,36].
Finally, alignment by cross-correlation of the extracellular and
NBD view averages allowed to orient both views. This revealed that
extensions of the extracellular views corresponds to an uneven
staining of the NBDs. Overall, the dimensions of the tetrameric ABCG2
of 15 nm and 11.5 nm, for the NBDs and the extracellular side,
respectively, were as expected signiﬁcantly smaller than those
reported for the octameric form of ABCG2 puriﬁed from High-Five
insect cells in Fos-choline 16 with a maximal diameter of 18 nm [10].3.4. Analysis of the oligomeric state of Flp-In-293 expressed His6-ABCG2
We next analyzed His6-ABCG2 expressed in Flp-In-293 cell lines
(Fig. 4). Membraneswere solubilized in different detergents including
DOTM and DDM and monomeric ABCG2 band ran at ~80 kDa likely
due to higher glycolysation than in Sf9 (Fig. 4A). Blue native gel
electrophoresis shows a single band running between the molecular
markers of 140 kDa and 440 kDa. The solubilized membrane
contained several proteins including three bands of ABCG2 that
were detected on immunoblot by BXP21 antibody and assigned to
monomer (*), dimer (**) and a higher molecular weight oligomer
(***) (Fig. 4C, lane 1 and 2).
We then performed the puriﬁcation of ABCG2 after incubation of
solubilized membranes with the functionalized lipid layer. It is worth
noting that the amount of proteins expressed in Flp-In 293 was lower
than in sf9 [47] and thus a lower amount of ABCG2 was expected
starting from10 μgrs of solubilized membrane and later bound to the
surface. After incubation of the solubilized membrane with the
functionalized layer followed by elution of bound proteins, a drastic
puriﬁcation of the protein content was obtained. Although very few
proteins were bound, a single faint bandwas found above the 250 kDa
marker at a molecular weight corresponding to the oligomeric ABCG2
(***) (lanes and 3). Image analysis of bound ABCG2 revealed squared
particles of 15 nm side with a 4 fold symmetry (supplementary
material) and with 4 densities of 5.5 nm each consistent with the size
of a single NBD.
Fig. 4. Oligomeric state of His6 ABCG2 expressed in Flp-In-293/ABCG2 cell lines.
(A) Membranes resuspended at 2 mg protein/ml were solubilized in 1% DOTM, 1%
DDM, 1% Fos-choline 16, and 18 mM CHAPS. For each detergent, 10 μl of supernatant
(left) and pellet (right) were analyzed by 8% SDS-PAGE and His6-ABCG2 was revealed
using the BXP-21 speciﬁc antibody and running at ~80 kDa. (B) 4-14% blue native gel of
His6-ABCG2, solubilized in DOTM, in either absence or presence of 10 mM NEM (lane 1,
lane 2) and in DDM (lane 3). (C) Silver stained SDS PAGE of solubilized membranes
(lane 1) and the corresponding western blot (lane 2) revealing monomeric (*), dimeric
(**) and oligomeric ABCG2 (***). Solubilized membrane was incubated and puriﬁed
after speciﬁc binding to the Ni++-NTA DOGS lipid surface. Although the amount of
bound protein was low, a main band of oligomeric ABCG2 was found (***) (lane 3).
(D) The 4-fold symmetrized average image of the NBD side of Flp-In-293 His6-ABCG2.
Scale bar=5 nm.
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ABCG2 is the human ABC transporter for which most different
oligomeric states have been reported leading to various controversies
but highlighting the tendency of this membrane protein to oligomer-
ize within or after extraction from the membrane (reviewed in
[48,49]). However, to address the question of the functional relevance
of speciﬁc oligomeric state of ABCG2, it is important to distinguish
oligomers present in the membrane from oligomers that may result
from the overexpression cells and/or themethodologies used for their
isolation and puriﬁcation.
Here, we compared the oligomeric state of ABCG2 after heterol-
ogous and homologous expression in Sf9 insect cell and in human Flp-
In-293/ABCG2 cell lines, respectively. Moreover, we used an im-
proved approach for the puriﬁcation of ABCG2 that allowed the
biochemical and the structural analysis by electron microscopy.
Overall, our data are consistent with a tetrameric state of ABCG2.
The human cells compared to the insect cells with the more
stringent quality control for the ER sorting, the post-traductional
modiﬁcations and the speciﬁc membrane composition, ensured the
most complete expression of ABCG2 [50,51]. The bottleneck of the low
amount of ABCG2 expressed in human cells that usually prevented
further structural analysis was solved through the speciﬁc concen-
tration of His-tagged protein onto a functionalized lipid surface.
Furthermore, the puriﬁcation at the surface was signiﬁcantly different
from the classical protocols of puriﬁcation using the successive afﬁnity
resins. In the former case, proteins of interest were puriﬁed at the
surface in presence of all the membrane components, while in the
latter case proteins were gradually puriﬁed by removingmost of other
components. In this context, cholesterol which is present during the
puriﬁcation by the lipid layer, as other lipids, was reported tospeciﬁcally increase both ATPAse and drugs transport activities
ABCG2 [52,53].
The oligomeric state of ABCG2within the membrane of living cells,
being unique or multiple and/or in dynamic equilibrium, is not yet
easily accessible experimentally. However, we believed that the
methodologies reported here ensured that the tetrameric organisa-
tion of ABCG2 is one of the oligomeric states, if not the unique
oligomeric state, present in the native membrane.
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